Amgen's Q1 earnings call revealed a mixed bag, with the company facing challenges due to the economic downturn, but also showing resilience in its international business and pipeline progress. The lowered revenue guidance and Enbrel sales decline are concerns, but management's cost-cutting measures and commitments to investing in key products and pipeline development are positives. 

[-1]